Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose GAL-054 pharmacology study in healthy volunteers
NL-OMON37672Active, not recruiting
- Sponsor
- Galleon Pharmaceuticals
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of GAL-054 in hypopnea and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Galleon Pharmaceuticals. Primary endpoint: Pharmacodynamic effects of GAL-054 compared with doxapram. Started Oct 2011; status: active, not recruiting.
02
Drugs
GAL-054
03
Conditions
hypopneachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON37672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37672.